Calcio 600 MK may be available in the countries listed below.
Ingredient matches for Calcio 600 MK
Calcium Carbonate is reported as an ingredient of Calcio 600 MK in the following countries:
- Colombia
International Drug Name Search
Calcio 600 MK may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Calcio 600 MK in the following countries:
International Drug Name Search
Flucillin may be available in the countries listed below.
Flucloxacillin sodium salt (a derivative of Flucloxacillin) is reported as an ingredient of Flucillin in the following countries:
International Drug Name Search
Apo-Citopram may be available in the countries listed below.
Citalopram is reported as an ingredient of Apo-Citopram in the following countries:
International Drug Name Search
Glipicontin may be available in the countries listed below.
Glipizide is reported as an ingredient of Glipicontin in the following countries:
International Drug Name Search
Rebone may be available in the countries listed below.
Ipriflavone is reported as an ingredient of Rebone in the following countries:
International Drug Name Search
Citalopram Tiefenbacher may be available in the countries listed below.
Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Citalopram Tiefenbacher in the following countries:
International Drug Name Search
Lamivudina Delta may be available in the countries listed below.
Lamivudine is reported as an ingredient of Lamivudina Delta in the following countries:
International Drug Name Search
Arendal may be available in the countries listed below.
Alendronic Acid is reported as an ingredient of Arendal in the following countries:
Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Arendal in the following countries:
International Drug Name Search
Promiten may be available in the countries listed below.
Dextran average molecular weight about 1000 (a derivative of Dextran) is reported as an ingredient of Promiten in the following countries:
International Drug Name Search
Regaine for Men Gel
Minoxidil 20 mg/g (2% w/w).
For excipients see section 6.1.
Cutaneous Gel (to be applied to the scalp).
Regaine for Men Gel is indicated for the treatment of alopecia androgenetica in men aged between 18 and 65.
Onset and degree of hair regrowth may be variable among users. Although trends in the data suggest that those users who are younger, who have been balding for a shorter period of time or who have a smaller area of baldness on the vertex are more likely to respond to Regaine for Men Gel, individual responses cannot be predicted.
Hair and scalp should be thoroughly dry prior to topical application of Regaine for Men Gel. A dose of 1 ml Regaine for Men Gel should be applied to the total affected areas of the scalp twice daily. The total daily dosage should not exceed 2 ml. If fingertips are used to facilitate drug application, hands should be washed afterwards.
It may take twice daily applications for four months or more before evidence of hair growth can be expected.
If hair regrowth occurs, twice daily applications of Regaine for Men Gel are necessary for continued hair growth. Anecdotal reports indicate that regrown hair may disappear three to four months after stopping Regaine for Men Gel application and the balding process will continue.
Users should discontinue treatment if there is no improvement after one year.
Children and the elderly
Not recommended. The safety and effectiveness of Regaine for Men Gel in users under 18 or over 65 years of age has not been established.
Regaine for Men Gel is contraindicated:
− in users with a history of sensitivity to minoxidil, ethanol, propylene glycol, carbomer and diisopropanolamine
− in users with treated or untreated hypertension
− in users with any scalp abnormality (including psoriasis and sunburn)
− in users with a shaved scalp
− if occlusive dressings or other topical medical preparations are being used.
Before using Regaine for Men Gel, the user should determine that the scalp is normal and healthy.
The user should stop using Regaine for Men Gel and see a doctor if hypotension is detected or if the patient is experiencing chest pain, rapid heart beat, faintness or dizziness, sudden unexplained weight gain, swollen hands or feet or persistent redness.
Users with known cardiovascular disease or cardiac arrhythmia should contact a physician before using Regaine for Men Gel.
Regaine for Men Gel is for external use only. Do not apply to areas of the body other than the scalp.
Hands should be washed thoroughly after applying the gel.
Regaine for Men Gel contains an alcohol base which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin and mucous membranes) the area should be bathed with large amounts of cool tap water.
Regaine for Men Gel contains propylene glycol, which may cause skin irritation.
Some users have experienced changes in hair colour and/or texture with use of Regaine for Men Gel.
Users should be advised to consult their doctor or pharmacist if they are concerned at any time during treatment with Regaine for Men Gel.
Users should be aware that, whilst extensive use of Regaine for Men Gel has not revealed evidence that sufficient minoxidil is absorbed to have systemic effects, greater absorption because of misuse, individual variability, unusual sensitivity or decreased integrity of the epidermal barrier caused by inflammation or disease processes in the skin (e.g. excoriations of the scalp, or scalp psoriasis) could lead, at least theoretically, to systemic effects.
Topical drugs, such as corticosteroids, tretinoin, dithranol or petrolatum which alter the stratum corneum barrier, could result in increased absorption of minoxidil if applied concurrently. Although it has not been clinically demonstrated, there exists the theoretical possibility of absorbed minoxidil potentiating orthostatic hypotension in patients concurrently taking peripheral vasodilators.
There is no evidence as to drug safety in human pregnancy nor is there evidence from animal work that it is free from hazard. Regaine for Men Gel should not be used during pregnancy or lactation.
Based on the pharmacodynamic and overall safety profile of minoxidil, it is not expected that Regaine for Men Gel would interfere with the ability to drive or operate machinery.
In placebo controlled trials of Regaine, the overall frequency of medical events in females in all body system categories was approximately five times that of males.
Several thousand patients have used topical minoxidil in clinical trials where a comparison with an inactive solution was made. Dermatological reactions (e.g. irritation, itching) occurred in patients using both solutions. This has been explained by the presence of propylene glycol in both the active and inactive solution. Regaine for Men Gel also contains propylene glycol.
Reactions reported in commercial marketing experience include: hypertrichosis (unwanted non-scalp hair including facial hair growth in women), local erythema, itching, dry skin/scalp flaking, and exacerbation of hair loss. Users should stop using Regaine for Men Gel if they experience persistent redness or irritation of the scalp.
Some consumers reported increased hair shedding upon initiation of therapy with Regaine for Men Gel. This is most likely due to minoxidil's action of shifting hairs from the resting telogen phase to the growing anagen phase (old hairs fall out as new hairs grow in their place). This temporary increase in hair shedding generally occurs two to six weeks after beginning treatment and subsides within a couple of weeks. If shedding persists (>2 weeks), users should stop using Regaine for Men Gel and consult their doctor.
Particular attention has been paid to body systems, such as cardiovascular and metabolic, which might have some relevance based on the pharmacology of minoxidil. There was no increased risk to users due to drug related medical reactions in these, or other, body system categories.
Users should stop using Regaine for Men Gel if they experience chest-pain, tachycardia, faintness, dizziness, sudden unexplained weight gain, or swollen hands or feet. Rare cases of hypotension have been reported.
Increased systemic absorption of minoxidil may potentially occur if higher-than-recommended doses of Regaine for Men Gel are applied to larger surface areas of the body or areas other than the scalp. There are no known cases of minoxidil overdosage resulting from topical administration of Regaine for Men Gel.
Because of the concentration of minoxidil in Regaine for Men Gel, accidental ingestion has the potential of producing systemic effects related to the pharmacological action of the drug (5 ml of Regaine for Men Gel contains 100 mg minoxidil, the maximum recommended adult dose for oral minoxidil administration in the treatment of hypertension). Signs and symptoms of minoxidil overdosage would most likely be cardiovascular effects associated with sodium and water retention and tachycardia. Fluid retention can be managed with appropriate diuretic therapy. Clinically significant tachycardia can be controlled by administration of a beta-adrenergic blocking agent.
Minoxidil is a powerful vasodilator. It was noticed that in patients with severe hypertension, about 80% developed hypertrichosis as a side-effect.
Individual responses to Regaine are variable and unpredictable.
The effect of Regaine 2% solution has been assessed in phase III clinical trials in men conducted over a 48 week treatment period. In these studies Regaine 2% solution was compared to the product vehicle without the minoxidil active ingredient. The primary efficacy criterion was non-vellus hair count in a 1.0cm2 reference area of affected scalp. The mean changes observed in this parameter in these studies were significantly in favour of Regaine 2% solution and were as follows:
Mean change in non-vellus hair count in reference 1cm2 area of scalp compared with baseline
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In addition, efficacy was further assessed by comparing photographs taken at various timepoints with baseline. Assessment was undertaken by patients using a 100 mm visual analogue scale where point 0 represented much less scalp coverage, 50 mm no difference and 100 mm much more scalp coverage. The results were as follows:
Patient evaluation of change in scalp coverage
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assessment was also undertaken by two blinded reviewers who compared photographs taken at baseline and after 48 weeks. Differences were assessed using a 7 point categorical scale viz:
Dense growth
Moderate growth
Minimal Growth
No change
Minimal loss
Moderate loss
Dense loss
The results were as follows:
Photographic Evaluation of Clinical Response (Reviewer 1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Photographic Evaluation of Clinical Response (Reviewer 2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based upon the photographic data around 40% of the patients experienced an increased scalp coverage after 48 weeks treatment with Regaine 2% solution as defined by regrowth of hair compared with 23% at an average for those who received vehicle alone. Around 19% treated with Regaine 2% solution experienced dense or moderate regrowth compared with around 7% who received vehicle alone. In addition 49% of patients who received Regaine 2% solution were adjudged to have no change between the photographic assessments of hair growth compared with 60% who received vehicle alone. Stabilisation of hair loss (i.e. regrowth or no loss) can therefore be expected in about 4 out of 5 patients using Regaine 2% solution compared with 3 out of 4 patients using vehicle alone.
The mechanism by which minoxidil stimulates hair growth is not fully understood, but minoxidil can reverse the hair loss process of androgenetic alopecia by the following means:
- increasing the diameter of the hair shaft
- stimulating anagen growth
- prolonging the anagen phase
- stimulating anagen recovery from the telogen phase
As a peripheral vasodilator minoxidil enhances microcirculation to hair follicles. The Vascular Endothelial Growth Factor (VEGF) is stimulated by minoxidil and VEGF is presumably responsible for the increased capillary fenestration, indicative of a high metabolic activity, observed during the anagen phase.
The failure to detect evidence of systemic effects during treatment with Regaine 2% solution reflects the poor absorption of topical minoxidil, which averages about 1.4% (range 0.3-4.5%) of the total applied dose from normal intact skin. Absorption is about 2% when applied topically to shaved scalps of hypertensive users.
Results of extensive pharmacokinetic studies indicate that the three major factors by which topical minoxidil absorption is increased are: increasing the dose applied, increasing the frequency of dosing and decreasing the barrier function of the stratum corneum.
Serum minoxidil levels and systemic effects resulting from administration of Regaine are governed by the drug's absorption rate through the skin. Following cessation of topical dosing, approximately 95% of the systemically absorbed drug is eliminated within 4 days. Minoxidil and its metabolites are excreted principally in the urine.
Preclinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential.
Cardiac effects of minoxidil in dogs are species-specific in terms of the low doses that cause profound haemodynamic effects and associated changes in the heart. Available data indicate that similar cardiac effects do not occur in humans treated topically or orally with minoxidil.
In rat fertility studies, minoxidil at dose levels between 3 and 80 mg/kg exhibited adverse effects on fertility. Animal reproduction toxicity studies have shown a risk to the foetus at exposure levels that in comparison to levels obtained in humans are very high (doses that ranged from 569- to 1139-fold anticipated human exposures) and showed signs of maternal toxicity.
Propylene glycol
Ethanol
Carbomer
Diisopropanolamine
Water
None known.
24 months
Do not store above 25˚C. Regaine for Men Gel is flammable.
Polyethylene bottle containing 60 ml of gel. An integral metered pump is included.
One press of the integral pump supplies 0.5 ml of gel. Regaine for Men Gel is flammable. Do not use while smoking, or near any naked flame or strong heat source. Avoid exposure of the container and contents to naked flames during use, storage and disposal.
McNeil Products Limited
Foundation Park
Roxborough Way
Maidenhead
Berkshire SL6 3UG
United Kingdom
PL 15513/0129
9 June 2005
11th April 2008
Rompirin may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Rompirin in the following countries:
International Drug Name Search
Atren may be available in the countries listed below.
Naproxen sodium salt (a derivative of Naproxen) is reported as an ingredient of Atren in the following countries:
International Drug Name Search
Isometeptene may be available in the countries listed below.
Isometeptene (DCIT) is known as Isometheptene Mucate in the US.
International Drug Name Search
Glossary
DCIT | Denominazione Comune Italiana |
Claritromycine Apotex may be available in the countries listed below.
Clarithromycin is reported as an ingredient of Claritromycine Apotex in the following countries:
International Drug Name Search
Flucloxacilline A may be available in the countries listed below.
Flucloxacillin sodium salt (a derivative of Flucloxacillin) is reported as an ingredient of Flucloxacilline A in the following countries:
International Drug Name Search
Cefonax may be available in the countries listed below.
Cefadroxil monohydrate (a derivative of Cefadroxil) is reported as an ingredient of Cefonax in the following countries:
International Drug Name Search
Monozide may be available in the countries listed below.
Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Monozide in the following countries:
Hydrochlorothiazide is reported as an ingredient of Monozide in the following countries:
International Drug Name Search
Prednisolone Beacons may be available in the countries listed below.
Prednisolone is reported as an ingredient of Prednisolone Beacons in the following countries:
International Drug Name Search
Ambiz may be available in the countries listed below.
Zolpidem is reported as an ingredient of Ambiz in the following countries:
International Drug Name Search
Lipista may be available in the countries listed below.
Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Lipista in the following countries:
International Drug Name Search
Terazosina Merck may be available in the countries listed below.
Terazosin hydrochloride (a derivative of Terazosin) is reported as an ingredient of Terazosina Merck in the following countries:
International Drug Name Search
Tenomet may be available in the countries listed below.
Cimetidine is reported as an ingredient of Tenomet in the following countries:
International Drug Name Search
Lamotrigin real may be available in the countries listed below.
Lamotrigine is reported as an ingredient of Lamotrigin real in the following countries:
International Drug Name Search
Arsumax may be available in the countries listed below.
Artesunate is reported as an ingredient of Arsumax in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
V03AB17,V04CG05
0000061-73-4
C16-H18-Cl-N3-S
319
Diagnostic agent
Urinary tract antiseptic
Antidote in methemoglobinemia
Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride
International Drug Name Search
Glossary
BAN | British Approved Name |
DCF | Dénomination Commune Française |
DCIT | Denominazione Comune Italiana |
IS | Inofficial Synonym |
OS | Official Synonym |
PH | Pharmacopoeia Name |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Apo-ISMN may be available in the countries listed below.
Isosorbide Mononitrate is reported as an ingredient of Apo-ISMN in the following countries:
International Drug Name Search
Mefenan may be available in the countries listed below.
Mefenamic Acid is reported as an ingredient of Mefenan in the following countries:
International Drug Name Search
Rydene may be available in the countries listed below.
Nicardipine hydrochloride (a derivative of Nicardipine) is reported as an ingredient of Rydene in the following countries:
International Drug Name Search
Insulin Glinux-N may be available in the countries listed below.
Insulin, Isophane human (a derivative of Insulin, Isophane) is reported as an ingredient of Insulin Glinux-N in the following countries:
International Drug Name Search
Cilpier may be available in the countries listed below.
Piperacillin sodium salt (a derivative of Piperacillin) is reported as an ingredient of Cilpier in the following countries:
International Drug Name Search
Acido Tranexamico may be available in the countries listed below.
Acido Tranexamico (DCIT) is known as Tranexamic Acid in the US.
International Drug Name Search
Glossary
DCIT | Denominazione Comune Italiana |
Acy may be available in the countries listed below.
Aciclovir is reported as an ingredient of Acy in the following countries:
International Drug Name Search
Risperdal Flas may be available in the countries listed below.
Risperidone is reported as an ingredient of Risperdal Flas in the following countries:
International Drug Name Search
Melovis may be available in the countries listed below.
Meloxicam is reported as an ingredient of Melovis in the following countries:
International Drug Name Search
Anapenil may be available in the countries listed below.
Phenoxymethylpenicillin potassium (a derivative of Phenoxymethylpenicillin) is reported as an ingredient of Anapenil in the following countries:
International Drug Name Search
JAN
0001824-50-6
C14-H14-Cl-N3-O4-S2
387
Diuretic agent
Antihypertensive agent
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(phenylmethyl)-, 1,1-dioxide
International Drug Name Search
Glossary
JAN | Japanese Accepted Name |
OS | Official Synonym |
Geneprami may be available in the countries listed below.
Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Geneprami in the following countries:
International Drug Name Search
In the US, Albalon (naphazoline ophthalmic) is a member of the drug class ophthalmic antihistamines and decongestants and is used to treat Eye Dryness/Redness and Eye Redness/Itching.
US matches:
Naphazoline hydrochloride (a derivative of Naphazoline) is reported as an ingredient of Albalon in the following countries:
International Drug Name Search
Algiderma may be available in the countries listed below.
Diethylamine Salicylate is reported as an ingredient of Algiderma in the following countries:
International Drug Name Search
Trigoa may be available in the countries listed below.
Ethinylestradiol is reported as an ingredient of Trigoa in the following countries:
Levonorgestrel is reported as an ingredient of Trigoa in the following countries:
International Drug Name Search
Exolit may be available in the countries listed below.
Bromhexine hydrochloride (a derivative of Bromhexine) is reported as an ingredient of Exolit in the following countries:
International Drug Name Search
C.M.P.200 may be available in the countries listed below.
Carbamazepine is reported as an ingredient of C.M.P.200 in the following countries:
International Drug Name Search
Metildigossina may be available in the countries listed below.
Metildigossina (DCIT) is also known as Metildigoxin (Rec.INN)
International Drug Name Search
Glossary
DCIT | Denominazione Comune Italiana |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Hépadial may be available in the countries listed below.
Dimecrotic Acid magnesium salt (a derivative of Dimecrotic Acid) is reported as an ingredient of Hépadial in the following countries:
International Drug Name Search
Hydrapres may be available in the countries listed below.
Hydralazine hydrochloride (a derivative of Hydralazine) is reported as an ingredient of Hydrapres in the following countries:
International Drug Name Search
Ratinal may be available in the countries listed below.
Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Ratinal in the following countries:
International Drug Name Search
Rephoren may be available in the countries listed below.
Calcium Acetate is reported as an ingredient of Rephoren in the following countries:
Magnesium Carbonate heavy (a derivative of Magnesium Carbonate) is reported as an ingredient of Rephoren in the following countries:
International Drug Name Search
Clopidogrel AAA may be available in the countries listed below.
Clopidogrel is reported as an ingredient of Clopidogrel AAA in the following countries:
International Drug Name Search
Folsäure-Hevert may be available in the countries listed below.
Folic Acid is reported as an ingredient of Folsäure-Hevert in the following countries:
International Drug Name Search
In the US, Povidine is a member of the following drug classes: antiseptic and germicides, vaginal anti-infectives.
Povidone-Iodine is reported as an ingredient of Povidine in the following countries:
International Drug Name Search
Ferro Gyn may be available in the countries listed below.
Ferrous Glycine Sulfate is reported as an ingredient of Ferro Gyn in the following countries:
Folic Acid is reported as an ingredient of Ferro Gyn in the following countries:
International Drug Name Search
Cefazolina Germed may be available in the countries listed below.
Cefazolin sodium salt (a derivative of Cefazolin) is reported as an ingredient of Cefazolina Germed in the following countries:
International Drug Name Search
Tyklid may be available in the countries listed below.
Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Tyklid in the following countries:
International Drug Name Search
KLEAN-PREP 69g, sachet powders for oral solution.
Each sachet of KLEAN-PREP contains the following active ingredients:
|
|
|
|
|
|
|
|
|
|
The content of electrolyte ions per sachet when made up to one litre of water is as follows:
|
|
|
|
|
|
|
|
|
|
For excipients, see 6.1.
A whitish powder which, when dissolved in water, gives a clear, colourless solution for oral administration.
For colonic lavage prior to diagnostic examination or surgical procedures requiring a clean colon, e.g. colonoscopy, barium enema or colonic resection.
Adults: Each sachet should be dissolved in 1 litre of water. The usual dose is up to 4 sachets taken at a rate of 250 ml every 10 to 15 minutes until the total volume is consumed or rectal effluent is clear, or as directed by the physician.
The solutions from all 4 sachets should be drunk within 4 to 6 hours. Alternatively, administration may be divided, for example, taking 2 sachets during the evening before the examination, and the remaining 2 sachets on the morning of the examination.
If administration is by nasogastric tube, the usual rate should be 20 to 30 ml/minute.
Children: There is no recommended dosage.
Renal patients: No dosage adjustment need be made.
Use in patients with known or suspected gastrointestinal obstruction or perforation, ileus, gastric retention, toxic colitis and toxic megacolon.
Congestive cardiac failure (NYHA class III and IV)
Hypersensitivity to any of the ingredients.
No solid food should be eaten for at least 2 hours before taking KLEAN-PREP. The product should only be administered with caution to patients with impaired gag reflex, reflux oesophagitis, or those with diminished levels of consciousness and patients with ulcerative colitis.
Unconscious, semi-conscious patients or patients prone to aspiration or regurgitation should be observed during administration especially if this is via the nasogastric route. There have been reports of pulmonary oedema resulting from aspiration of macrogol lavage solutions requiring immediate treatment.
Although not expected due to the isotonic composition of the product, cases of electrolyte disturbances have been rarely reported in at-risk patients. Therefore, KLEAN-PREP should be used with care in patients at risk of electrolyte disturbance, such as patients with renal failure, mild (NYHA class I and II) congestive cardiac impairment (see also section 4.3), or those simultaneously treated with diuretics.
Should abdominal distension or pain arise, the rate of administration should be slowed down or temporarily stopped until symptoms subside.
KLEAN-PREP contains aspartame, which is metabolised to phenylalanine. This may be harmful for patients with phenylketonuria.
Caution should be used in the administration of KLEAN-PREP to elderly, fragile or debilitated patients.
Oral medication taken within one hour of administration of KLEAN-PREP may be flushed from the gastro-intestinal tract and not absorbed.
The preparation should only be used during pregnancy and lactation if considered essential by the physician. There is no experience of use during pregnancy. The purpose and mechanisms of use should be borne in mind if the physician is considering administration.
There is no known effect on the ability to drive and use machines.
The most commonly experienced undesirable effects are gastrointestinal in nature. The following Adverse Events have been observed in post-marketing experience and therefore the frequencies are not known:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transient increases in blood pressure have been observed in association with bowel preparations.
In case of gross accidental overdosage, where diarrhoea is severe, conservative measures are usually sufficient; generous amounts of fluid, especially fruit juices, should be given.
ATC Code: A06A D
Macrogol 3350 exerts its effects by virtue of its osmotic effect in the gut, which induces a laxative effect. Electrolytes are present in the formulation and are exchanged across the intestinal barrier (mucosa) with serum electrolytes and water to prevent the occurrence of potential clinically significant variations of net electrolyte or net water balance.
Macrogol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of the defecation.
Macrogol 3350 is unchanged along the gut. It is virtually unabsorbed from the gastro-intestinal tract. Any macrogol 3350 that is absorbed is excreted via the urine.
Preclinical studies provide evidence that macrogol 3350 has no significant systemic toxicity potential.
Vanilla flavour
Aspartame.
None are known.
|
|
|
|
Sachets: Store in a dry place. Do not store above 25°C.
Reconstituted solution: Store in a refrigerator (2 – 8°C)
Sachets containing 69gm white powder, in a box of 4 sachets.
The solution should be used within 24 hours.
Norgine Limited
Norgine House
Widewater Place
Moorhall Road
Harefield
UXBRIDGE
Middlesex UB9 6NS
United Kingdom.
PL: 00322/0068.
August 1991/March 1997.
Feb 2011
Bupivacaina Angelini may be available in the countries listed below.
Bupivacaine hydrochloride (a derivative of Bupivacaine) is reported as an ingredient of Bupivacaina Angelini in the following countries:
International Drug Name Search
Maveral may be available in the countries listed below.
Fluvoxamine maleate (a derivative of Fluvoxamine) is reported as an ingredient of Maveral in the following countries:
International Drug Name Search
Lansoprazol KRKA may be available in the countries listed below.
Lansoprazole is reported as an ingredient of Lansoprazol KRKA in the following countries:
International Drug Name Search
Pantosec-D may be available in the countries listed below.
Domperidone is reported as an ingredient of Pantosec-D in the following countries:
Pantoprazole is reported as an ingredient of Pantosec-D in the following countries:
International Drug Name Search
Colistin Link may be available in the countries listed below.
Colistin sulphomethate sodium (a derivative of Colistin) is reported as an ingredient of Colistin Link in the following countries:
International Drug Name Search
Ximocef may be available in the countries listed below.
Cefpodoxime is reported as an ingredient of Ximocef in the following countries:
International Drug Name Search
Cardigard may be available in the countries listed below.
Carvedilol is reported as an ingredient of Cardigard in the following countries:
International Drug Name Search
Lecimar may be available in the countries listed below.
Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Lecimar in the following countries:
International Drug Name Search
Paclitaxel-Teva may be available in the countries listed below.
Paclitaxel is reported as an ingredient of Paclitaxel-Teva in the following countries:
International Drug Name Search
Feedmix TS may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfamethoxazole is reported as an ingredient of Feedmix TS in the following countries:
Trimethoprim is reported as an ingredient of Feedmix TS in the following countries:
International Drug Name Search
Gizende may be available in the countries listed below.
Heparin sodium salt (a derivative of Heparin) is reported as an ingredient of Gizende in the following countries:
International Drug Name Search
Ketoprofen SR may be available in the countries listed below.
Ketoprofen is reported as an ingredient of Ketoprofen SR in the following countries:
International Drug Name Search
Bassamin may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Bassamin in the following countries:
International Drug Name Search
Clinax may be available in the countries listed below.
Minocycline is reported as an ingredient of Clinax in the following countries:
Sulindac is reported as an ingredient of Clinax in the following countries:
International Drug Name Search
Flagyl Vaginal may be available in the countries listed below.
Metronidazole is reported as an ingredient of Flagyl Vaginal in the following countries:
International Drug Name Search
Halfdopa may be available in the countries listed below.
Methyldopa is reported as an ingredient of Halfdopa in the following countries:
International Drug Name Search
Balsoclase may be available in the countries listed below.
Carbocisteine is reported as an ingredient of Balsoclase in the following countries:
Pentoxyverine citrate (a derivative of Pentoxyverine) is reported as an ingredient of Balsoclase in the following countries:
International Drug Name Search
In the US, Letrozole (letrozole systemic) is a member of the following drug classes: aromatase inhibitors, hormones/antineoplastics and is used to treat Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer - Metastatic and Female Infertility.
US matches:
Rec.INN
L02BG04
0112809-51-5
C17-H11-N5
285
Antineoplastic agent
Enzyme inhibitor, aromatase
Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-
International Drug Name Search
Glossary
BAN | British Approved Name |
IS | Inofficial Synonym |
OS | Official Synonym |
PH | Pharmacopoeia Name |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |